6533b855fe1ef96bd12b1441
RESEARCH PRODUCT
CXC chemokine ligand 4 (CXCL4) is predictor of tumour angiogenic activity and prognostic biomarker in non-small cell lung cancer (NSCLC) patients undergoing surgical treatment.
Dainis KrievinsDarja SvirinaInta JaunalksneArtjoms SpaksDonats BreivaIrina SpakaIlmars Tracumssubject
0301 basic medicineOncologymedicine.medical_specialtyPathologyChemokineLung NeoplasmsAngiogenesisHealth Toxicology and MutagenesisClinical Biochemistrynon-small cell lung cancer (NSCLC)Platelet Factor 4BiochemistryDisease-Free Survival03 medical and health sciences0302 clinical medicineVascularityInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansStage (cooking)biologyNeovascularization Pathologicbusiness.industryLigand (biochemistry)medicine.disease030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisbiology.proteinImmunohistochemistrymedicine.symptomNeoplasm Recurrence LocalbusinessPlatelet factor 4Biomarkersdescription
AbstractObjective: To evaluate the association of CXC chemokine ligand 4 (CXCL4) plasma levels with tumour angiogenesis in non-small cell lung cancer (NSCLC) and to assess association of CXCL4 with clinical outcomes.Patients and methods: Fifty patients with early stage NSCLC who underwent pulmonary resection. CXCL4 levels were analysed by ELISA. Angiogenesis was assessed by immunohistochemistry, and microvessel density (MVD) count.Results: There was positive correlation between MVD and CXCL4 levels. Patients with higher CXCL4 levels had worse overall and disease-free survival.Conclusions: Plasma levels of CXCL4 are associated with tumour vascularity. Increased CXCL4 levels in NSCLC patients undergoing treatment may indicate active cancer-induced angiogenesis associated with relapse and worse outcome.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-04-22 | Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals |